CTLT vs. SRPT, UTHR, ROIV, LEGN, ASND, RDY, KRTX, CERE, ITCI, and VKTX
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Roivant Sciences (ROIV), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Catalent has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 782 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 59.37% of users gave Catalent an outperform vote.
Sarepta Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Catalent has a net margin of -29.91% compared to Catalent's net margin of -43.11%. Sarepta Therapeutics' return on equity of -2.43% beat Catalent's return on equity.
86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.4% of Sarepta Therapeutics shares are held by insiders. Comparatively, 0.3% of Catalent shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Sarepta Therapeutics had 13 more articles in the media than Catalent. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 7 mentions for Catalent. Sarepta Therapeutics' average media sentiment score of 1.11 beat Catalent's score of 0.18 indicating that Catalent is being referred to more favorably in the news media.
Sarepta Therapeutics presently has a consensus target price of $156.60, suggesting a potential upside of 21.61%. Catalent has a consensus target price of $52.46, suggesting a potential downside of 6.19%. Given Catalent's stronger consensus rating and higher possible upside, research analysts plainly believe Sarepta Therapeutics is more favorable than Catalent.
Summary
Sarepta Therapeutics beats Catalent on 10 of the 18 factors compared between the two stocks.
Get Catalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
Related Companies and Tools
